This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Spheramine
Description: Spheramine consists of dopamine-producing human retinal pigment epithelial (RPE) cells adhered to spherical microscopic carriers to enhance the cells’ survival when injected in the brain. Spheramine is implanted in the area requiring dopamine using a stereotaxic surgical procedure, which does not require general anesthesia. The microsopic carriers eliminate the need for immunosuppressants.
Deal Structure: In January 2000, Titan entered into a sublicense agreement with Schering granting Schering exclusive worldwide commercialization rights to Spheramine. Under the agreement, Titan will collaborate with Schering on manufacturing and clinical development of cell therapy for the treatment of Parkinsons disease. Titan will receive funding for development activities, as well as potential reimbursement of certain prior research and development expenses. Schering will fully fund, and manage in collaboration with Titan, all future pilot and pivotal clinical studies, and manufacturing and development activities. Schering will pay Titan a royalty on net sales of Spheramine. Titan is also obligated to pay a portion of the royalties to New York University.
In 2006, Bayer acquired Schering AG.
Partners: Titan Pharmaceuticals, Inc.
Pink Sheet R&D In Brief
Pink Sheet Titan’s Spheramine Fails In Parkinson’s
Additional information available to subscribers only: